Biomarkers of drug efficacy and toxicity are becoming a key need in the drug development process. Mass spectral-based proteomic technologies are ideally suited for the discovery of protein biomarkers in the absence of any prior knowledge of quantitative changes in protein levels. The success of any biomarker discovery effort will depend upon the quality of samples analysed, the ability to generate quantitative information on relative protein levels and the ability to readily interpret the data generated. This review will focus on the strengths and weaknesses of technologies currently utilised to address these issues.
INTRODUCTION
Advances in protein analytical technologies are finding broad application in drug discovery programmes. One area of intense interest is in the area of biomarker discovery. Biomarkers are indicators of a biological process and may be genes, proteins, small molecules or metabolites. Intense effort has been applied to the discovery of genetic associations in complex diseases. Single nucleotide polymorphisms (SNPs) have been used as biomarkers of disease association and susceptibility. 1 SNPs provide valuable information that may be used in the selection of treatments and prediction of outcomes, although they are not useful for measurement of these outcomes. While SNPs indicate the potential for disease susceptibility, it is the activity of the resultant protein that actually determines this. Biomarkers of drug efficacy and toxicity have the potential to speed the process of drug development, as they may provide indications of drug action at earlier stages than clinical endpoints. When successfully applied, biomarker analysis can have an impact on the length and cost of clinical trials.
With the wealth of information generated from genomic sequencing projects, attention has begun to shift to the study of the resultant protein component. Protein biomarkers also provide predictive information, but will also be useful in monitoring the effects of drug treatments. Measurement of protein changes can be accomplished in body fluids as well as tissues and cells, which is a particular advantage in a clinical setting. The large volume of data acquired in protein-based studies demands application of higher throughput, more sensitive techniques for the discovery of suitable biomarkers.
Until recently, biomarker discovery resulted from intensive study of individual proteins, development of enzyme-linked immunosorbent assay-type assays and measurements on control and perturbed systems. It is becoming increasingly clear that the predictive utility of individual biomarker proteins may be limited. As an alternative, panels of proteins may be required to accurately gauge the level of perturbation of a biological system. While a variety of multiplex assay technologies are being developed to facilitate the rapid analysis of multiple protein biomarkers simultaneously from a single sample, [2] [3] [4] [5] [6] most are limited by the need to know which protein is required to be monitored and to develop specific reagents (most frequently specific antibody pairs) for these proteins. A few approaches, which do use non-antibody binding agents, rely on non-specific interactions (ion exchange, reversed phase etc 7 ), which complicates the identification of potential biomarkers. The problem is finding all of the relevant biomarkers without knowing in advance what they are. Integration of protein separation technologies, some of which have been in use for decades, with high throughput mass spectral techniques are providing solutions to this need.
Numerous strategies have been applied in the area of biomarker discovery. Mass spectral technologies have been widely used in concert with separations technologies such as two-dimensional polyacrylamide gels 8 and chromatographic techniques. 9 Mass spectrometry has also been used to identify and quantify proteins in complex mixtures without prior separations. 10 Recent developments in quantification using mass spectral techniques provide examples of how this technology may be utilised to identify biomarkers in complex samples in a high throughput fashion. Application of this technology to biological fluids may afford the ability to measure and identify protein changes without a priori knowledge of protein changes occurring in response to a particular perturbation. While quite powerful, protein changes identified by these strategies will still only provide candidate biomarkers. Validation of these candidates will require sophisticated bioinformatics technologies to analyse the data and assign statistical significance and confidence to protein measurements. Validation will ultimately provide tools by which experts in the biology of a particular system may visualise the data and draw meaningful conclusions as to the context of a biomarker or panel of biomarkers.
This review will focus on strategies for the identification of protein biomarker candidates, with emphasis on the issues surrounding the adaptation of separations and identification technologies to high throughput analysis of complex biological fluids. Biological fluids are preferred in biomarker measurements because samples may be obtained by relatively noninvasive methods such as drawing blood. They also have the advantage over cell or tissue samples that the protein components are all in a soluble form in a single compartment. The fluids most frequently studied are serum, plasma and cerebrospinal fluid (CSF). The process of biomarker discovery in these fluids may be subdivided into three areas: 1) sample collection and preparation, 2) separation and quantification and 3) data analysis. It is essential in the effective identification of valid biomarkers that the error inherent in each of these components be accurately determined and that only quantitative changes that have statistical significance be used to suggest biomarker candidates. Otherwise, a huge amount of effort can be spent exploring changes that are simply noise in the complex system under analysis.
SAMPLE COLLECTION AND PREPARATION
One of the largest sources of variability in the biomarker discovery process is subject-to-subject variability. Many factors influence the protein concentration of a biological fluid, including normal metabolism, circadian rhythms of protein production, degradation and environmental conditions. In addition, following sample collection, modifications of proteins may occur via proteolysis, protein aggregation and chemical modifications, such as oxidation. In order to minimise these variations, sample collection and storage conditions must be standardised within any study. Factors to be considered include the time of day the samples are collected, the length of time samples are kept at room temperature and whether to process the samples immediately or freeze them. If samples are to be stored frozen, the number of thaws should be minimal. As a result, it may be necessary to subaliquot samples such that large volumes do Bioinformatics technologies will be necessary to analyse and evaluate the large volume of data not need to be thawed in order to remove small aliquots for analysis at different times. Without attention to sample quality, differences in protein levels resulting from external factors may be misinterpreted as biological effects.
Prior to analysis by mass spectral techniques, most biological fluids will need to be processed to reduce protein complexity. Fluids like serum and plasma are comprised of thousands of different proteins but a relative few proteins dominate. 11 Albumin and the immunoglobulins (Igs) represent about 75 per cent of the protein concentration of these fluids. These proteins are similarly abundant in CSF. Removal of these proteins prior to analysis allows visualisation of proteins of lower abundance. A number of strategies have been developed around removal of these two proteins. Many of these involve affinity chromatography steps. For example, protein A and protein G are bacterial proteins that have affinities primarily for the constant region of the IgG heavy chain. 12 Resins on which these proteins are immobilised can remove most of the IgG in a sample with fairly high specificity. Albumin removal is not as easily accomplished. One of the most common methods for albumin removal from fluids is the use of columns containing an immobilised dye such as Cibacron blue. This dye interacts strongly with albumin and may be used to deplete this protein from samples. Figure 1 shows a sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel of a serum sample before and after passage over a Cibacron blue column. It is evident that the heavy albumin band at 66 kDa is greatly reduced by the dye resin and that the relative proportions of many lower abundance proteins have been increased. The drawback to this technique is that the dye resin is not absolutely specific for albumin and is known to interact with other proteins possessing a dinucleotide fold. 13 Electrophoresis of the bound fraction reveals that many other proteins have been bound to varying extents ( Figure 1, lane 3) . This could introduce variability and, therefore, the bound fraction should be retained and analysed in any biomarker discovery project. Other albumin removal techniques are being developed and these include anti-albumin antibodies 14 and albumin-specific peptides. 15 Generally, these techniques are more costly than the dye columns, which is why they have not yet been widely adopted.
Additional protein fractionation techniques may be performed at this stage of sample processing. The most commonly employed are gel electrophoresis techniques. Twodimensional gel electrophoresis has been utilised for decades 16, 17 and is capable of resolving thousands of protein spots. More recently, chromatographic prefractionation techniques have been employed in gel-free analytical Sample fractionation may increase the dynamic range of protein measurement Figure 1 : Removal of albumin from serum with Cibacron blue chromatography. Rat serum was passed over a commercial Cibacron blue resin (Affygel blue, Bio-Rad). The flow through fraction was collected and analysed on a 4-20% sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel under reducing conditions. Later, resin with bound protein was treated with SDS sample buffer to remove the retained proteins. Lane 1: rat serum. Lane 2: proteins not bound to the Cibacron blue resin. Lane 3: bound proteins released from the Cibachron blue resin procedures. 9 The gel-free procedures are gaining popularity because advances in liquid chromatography/mass spectrometry (LC/MS) technologies have made the analysis of highly complex mixtures possible. Simplification of complex mixtures without using gels has been accomplished by isolation of classes of peptides, such as glycopeptides, 18 and by liquid phase isoelectric focusing of mixtures prior to mass spectral analysis. 19 In all of these strategies, great care must be taken in order to ensure reproducible performance, to avoid the introduction of variability.
The final step in sample processing typically involves digestion of proteins into peptides using proteolytic enzymes. The most commonly used enzyme is trypsin, since the resultant peptides are compatible with mass spectral analysis. Many different methods have been developed to digest complex mixtures of proteins in solution. Factors that influence the success of the technique include 1) global reduction/alkylation of proteins and 2) inclusion of chaotropic salts or other protein solubilising agents. Reduction and alkylation of cysteines facilitates the unfolding of proteins, which exposes protease-sensitive sites. This unfolding also promotes protein aggregation, which is why solubilising agents are needed. By adjusting the concentration of the solubilising agents, such that aggregation is minimised but proteolytic enzymes are still active, efficient digestion may be achieved. The resulting peptide mixture may now be analysed by LC/MS methods to identify and quantify proteins in the mixture.
SEPARATION/ IDENTIFICATION/ QUANTIFICATION
The analysis of mixtures of peptides by mass spectrometry is possible by interfacing high-performance liquid chromatography (HPLC) separations with electrospray ionisation techniques. 20 Reversed-phase solvents and ion pairing agents are volatile and thus compatible with this soft ionisation process. In this application, the mass spectrometer functions like an HPLC detector, although much more information may be acquired than with a typical detector. In addition to total ion current, the mass spectrometer continuously acquires mass information on the molecular species that are eluting from the column at any point in time. Many instruments, such as the ion trap mass spectrometer, may be programmed to subject peptides to fragmentation in the tandem mass spectrometric (MS/MS) mode, which generates peptide sequence information that can be used to identify peptides. 21 In this mode, peptides are fragmented by collisions with monoatomic gas molecules. Typically, the weakest bond in peptides is the peptide bond between amino acids, and the fragments that are generated will differ in mass by discrete quantities that are defined by the sequence of amino acids in the peptide. 22 An example of such a chromatogram is shown in Figure 2 . Figure 2A displays the total ion current of a tryptic digest of a serum sample (after removal of albumin and IgG) separated on a C-18 reversedphase column. Figure 2B displays the mass spectrum of a particular time region of the chromatogram, indicating that, at any point in time, multiple peptides may be eluting from the column. In a datadependent mode, the mass spectrometer may alternate between the MS and the MS/MS mode. The computer controller can identify the most abundant peak in the spectrum, select this ion for fragmentation in the MS/MS mode and then return to the MS mode and select the next most abundant ion for fragmentation. Figure 2C displays the MS/MS fragmentation pattern collected for ion 980.7 in Figure 2B . These fragmentation spectra may be used to search databases of protein sequences utilising programs such as SEQUEST 23 or Masscot. 24 These algorithms compare theoretical fragmentation patterns of peptides in the database to the actual fragmentation pattern obtained and return Fragmentation and peptides on the mass spectrometer may be used to identify the sequence of the peptide the highest correlation matches. Many spectra may be searched in automated fashion, although some visual inspection is still required for peptide matches with relatively low correlation scores. Many efforts have been initiated to improve the quality of these correlations [25] [26] [27] [28] but much room for improvement exists.
While separation and identification techniques are available, quantification of mass spectra is at an earlier stage of development. The most widely utilised technologies for quantification of peptides and proteins by mass spectrometry are the isotope tagging techniques. The most popular of these is the isotope-coded affinity tag (ICAT) technology. 29 This technique allows relative quantification of peptides in two different samples by labelling one sample of protein with a deuterated alkylating agent while the other sample is labelled with the same alkylating agent without deuterium. The two samples are then mixed together, digested with proteolytic enzyme and processed by LC/MS. Peptides from the different samples are separated by 8 mass units and the heights of the peptide pairs are compared to provide information on the relative levels of peptide in each sample, which can then be related back to the protein from which the peptides were derived. Many related isotopic labelling techniques have been reported. 30, 31 The requirement for paired analysis limits the scale to which these techniques may be practised. A comparison of patient samples, in which ten samples from a control group were compared to ten samples from a treatment group, would require 100 separate analytical runs to be conducted. Statistical rigor would require reciprocal labelling to be carried out, doubling the number of analytical runs to 200. The volume of data to be processed and the resultant expense of these techniques limits their application. 32 The ion current for an individual peptide ion may be extracted from the total ion chromatogram. This is illustrated in Figure 3 . From the total ion chromatogram ( Figure 3A ), the ion current for ion 980.7 was extracted ( Figure 3B) . The height or the area of this extracted peak may be calculated.
Comparison of the area of this peak to the corresponding peak from a second sample may provide information on the relative level of the peptide and thus the protein from which it derived. For this technique to succeed, total protein levels in the two samples must be normalised and sampleprocessing methods must be highly reproducible. Samples to be compared should be similar in nature, as large differences in composition may introduce ion-suppression effects. Spectra to be compared should all be generated on the same instrument in close succession. Additionally, separation technologies must be well validated to ensure reproducible retention times and responses. As with the isotopic labelling techniques, a wealth of data may be generated. This results in the need for bioinformatics and statistical methods for processing and interpreting the data.
DATA ANALYSIS
The initial analysis of mass spectral data typically involves database searching using the algorithms mentioned in the previous section. The resultant tables of identified proteins also contain scoring parameters that assign confidence to individual peptide results. When these scores are high, peptide identifications can be accepted without the need for visual inspection of the spectra. Similarly, very low scores indicate random correlation and may be discarded. The area of difficulty that currently exists is in the intermediate confidence scores. In some cases, peptide assignments with scores in this intermediate range may be correct. These scores may derive from low intensity spectra, peptides with high charge states (. +3) and large peptides, among other factors. The difficulty arises because there will be incorrectly identified peptides in the intermediate scoring range and one must visually inspect MS/MS spectra in this range to determine the difference between correct and incorrect identifications. This is an area of active research and many groups are developing improved scoring parameters and post-search data analysis Peptide identification by database searching programs may still require visual inspection of spectra Figure 3 : Extracted ion chromatogram of a single peptide from a total serum sample. Liquid chromatography mass spectrometry (LC/MS) spectrum of the serum digest described in Figure  2 : A) base peak display of the total ion chromatogram of the LC separation of the peptides; B) ion current for m/z 980.7 extracted from the total chromatogram programs. [25] [26] [27] [28] For quantitative applications, peak heights or peak areas need to be extracted, samples compared and the validity statistically evaluated. This area is far less standardised than database searching and thus not many commercially available software packages exist. Software is available for individual instruments, like the Q-Tof mass spectrometer, to evaluate ICAT experiments. 33 Even these packages, however, may need to be adapted to an individual approach. A major challenge is in the application of these techniques in an automated fashion. To generate the statistical power needed for a biomarker discovery programme, many samples must be run and analysed. Software for automation of MS/MS searching, evaluation of data quality and quantification of MS data must be developed for this to occur. Thus, the mass spectrometrist must work closely with specialists in bioinformatics and software development in order to devise solutions to these barriers.
Once primary analysis is accomplished, software packages for additional data manipulation and visualisation do exist. Spreadsheet programs like Microsoft Excel or JMP may be used to tabulate data and perform statistical analyses. A second category of tools includes those for table storage and joining. Through these, expanded tables of primary data can be stored directly into a database such as Microsoft Access. The data may then be merged with information about proteins, such as data from the Gene Ontology database, pathway information, experimental details and additional analyses. This will facilitate biological interpretation and begin the data mining process. The data could be parsed at this stage, although it may be unwieldy to manually sift through large tables of data. A third category of tools is therefore required: those for data reduction and visualisation. Graphical tools provide accessible techniques for visualisation of data through pattern recognition. Software packages like Spotfire are well suited for this. Graphical representation of single or multiple tables of data enables interactive queries of the tables' contents using sliders and buttons that update the graphics in real time. Additional tools in Spotfire allow viewers for biological pathways and Gene Ontology to interact with the data in real time. The power of the database architecture is that it enables one database to create multiple views of the same data for different people, or views incorporating different datasets for different applications.
At the highest level, tools for cluster analysis are needed. It is increasingly apparent that individual protein changes will only rarely provide biomarkers. Multiple, interdependent changes in panels of proteins may be more useful in prediction and measurement of outcome applications. Many statistical tools have been developed for analysis of changes in gene expression patterns from microarrays. Approaches building on these tools have begun to be applied to proteomic data sets; 34 however, great care must be taken in the design of the studies and interpretation of the resulting data. 35 
CONCLUSION
Applications of mass spectral-based technologies are providing solutions for the discovery of novel biomarkers. Once discovered, these biomarker candidates must be validated and ultimately assayed in a format that lends itself to high throughput analysis. The emerging field of multiplex assay technology 36 offers a complementary approach to the successful implementation of biomarker measurements. Mass spectral approaches will provide information defining the proteins of interest. While these technologies provide the ability to automate separation, identification and quantification technology, and more focused and higher throughput methods based on multiplexed antibody assays may be designed, based on the information generated from mass spectral approaches. These assays will be capable of handling large numbers of samples in a clinical Statistical analysis software and data visualisation programs are used to evaluate the data Multiplexed assay technologies provide complementary approaches for biomarker validation setting, and the combination of these technologies promises to change the landscape of clinical drug discovery in the near future.
